Application No. 09/050,366

Amdt. Date September 15, 2003

Reply to Official Action of June 13, 2003

Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

Claims 1-21. (Cancelled)

Claim 22. (Currently Amended) A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and abdominal/visceral obesity to decrease insulin resistance, wherein said method comprises administering to said patient human growth hormone or a functional analog derivative thereof in an amount effective for decreasing insulin resistance of said patient.

Claim 23. (Currently Amended) The method of according to claim 22 wherein the <u>human</u> growth hormone comprises <u>recombinant</u> human growth hormone or a functional analog thereof.

Claims 24-40. (Cancelled)

Claim 41. (Currently Amended) A The method according to claim $\frac{22}{23}$, wherein said method comprises administering recombinant human growth hormone at about 9.5 μ g/kg daily.

Claim 42. (Previously Presented) The method according to claim 22, wherein the treatment increases insulin sensitivity of the patient.